Charles River Laboratories International, Inc. (CRL)
Charles River Laboratories International, Inc. (CRL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Charles River Laboratories International, Inc. (CRL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Charles River Laboratories International, Inc. (CRL) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Charles River Laboratories International, Inc. (CRL) Presents at 46th Annual William Blair Growth Stock Conference Transcript
Charles River Laboratories (CRL) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Charles River (CRL) Reliance on International Sales: What Investors Need to Know
Evaluate Charles River's (CRL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Charles River Laboratories International Q1 Earnings Call Highlights
Charles River Laboratories International NYSE: CRL reported first-quarter 2026 results that management said were in line to slightly ahead of its prior outlook, while reaffirming its full-year organic revenue and non-GAAP earnings guidance and outlining a refreshed strategic framework under new Chief Executive Officer Birgit Girshick.
LH vs. CRL: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?
Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript
Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript
Charles River Q1 Review: Near-Term Stability But Long-Term Risks (Downgrade)
Charles River Laboratories is downgraded to 'Sell' as shares have rallied 57% in the past year, outpacing fundamentals. Despite Q1 stabilization, organic revenue declined 1.5% and margins compressed, with near-term growth muted and longer-term AI and regulatory risks looming. CRL maintains 2026 EPS guidance of $10.80–$11.30 but trades at 17.5x forward earnings—still at a discount to its history but not considered cheap.
CRL Q1 Earnings & Revenues Top Estimates, Margins Crash, Stock Down
Charles River beats Q1 earnings and revenue estimates, but margin declines and weak organic growth in key segments send shares lower in pre-market.
Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Charles River Laboratories (CRL) Surpasses Q1 Earnings and Revenue Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.06 per share, beating the Zacks Consensus Estimate of $1.96 per share. This compares to earnings of $2.34 per share a year ago.
Charles River (CRL) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Evaluate the expected performance of Charles River (CRL) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
